First Tracks Biotherapeutics (TRAX) director receives stock options and RSU grant

Q: How do the new TRAX stock options granted to Dennis M. Fenton vest?

The stock options for 7,000 shares vest in 1/12 increments monthly , beginning on June 12, 2026 . Vesting continues each month until fully vested, provided Fenton continues to provide service to First Tracks Biotherapeutics on each vesting date.

Q: When do Dennis M. Fenton’s restricted stock units in First Tracks Biotherapeutics (TRAX) vest?

Fenton’s 2,500 restricted stock units vest as to 100% of the total units on the date of First Tracks Biotherapeutics’ 2027 annual meeting of shareholders , so long as he continues to provide service to the company through that vesting date.

Q: What is the exercise price and expiration for Dennis M. Fenton’s TRAX stock options?

The granted stock options carry an exercise price of $17.81 per share and are scheduled to expire on May 11, 2036 . These options give Fenton the right to buy First Tracks Biotherapeutics common stock at that fixed price until expiration.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

4/A

Rhea-AI Filing Summary

First Tracks Biotherapeutics director Dennis M. Fenton received new equity awards. On May 12, 2026, he was granted stock options for 7,000 shares of common stock at an exercise price of $17.81 per share, vesting monthly over one year starting June 12, 2026.

He was also granted 2,500 restricted stock units, each representing one share of common stock for no cash payment. These RSUs vest in full at the company’s 2027 annual meeting of shareholders, if he continues providing service through that date.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider FENTON DENNIS M

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	2,500	$0.00	--
Grant/Award	Stock Option (right to buy)	7,000	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 2,500 shares (Direct, null); Stock Option (right to buy) — 7,000 shares (Direct, null)

Footnotes (1)

Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Stock options granted: 7,000 options Option exercise price: $17.81 per share Option expiration: May 11, 2036 +5 more

8 metrics

Stock options granted 7,000 options Grant on May 12, 2026 to director Dennis M. Fenton

Option exercise price $17.81 per share Exercise price for 7,000 stock options

Option expiration May 11, 2036 Expiration date of granted stock options

RSUs granted 2,500 RSUs Restricted stock units granted May 12, 2026

Option vesting start June 12, 2026 Monthly vesting begins, 1/12 each month

RSU vesting event 2027 annual meeting RSUs vest 100% on 2027 shareholder meeting date

Shares underlying options 7,000 shares Common stock underlying the stock options

Shares underlying RSUs 2,500 shares Common stock underlying the restricted stock units

Key Terms

Stock Option (right to buy), Restricted Stock Unit, exercise price, annual meeting of shareholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Restricted Stock Unit financial

"security_title: Restricted Stock Unit"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

exercise price financial

"conversion_or_exercise_price: 17.8100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of shareholders financial

"on the date of the Issuer's 2027 annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

vests financial

"The stock option vests as to 1/12 of the total shares monthly"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 04:11 PM Accepted by SEC EDGAR 06/12/2026 - 04:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FENTON DENNIS M

(Last)

(First)

(Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/14/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	05/12/2026		A		2,500		⁽²⁾	⁽²⁾	Common Stock	2,500	$0	2,500	D
Stock Option (right to buy)	$17.81	05/12/2026		A		7,000		⁽³⁾	05/11/2036	Common Stock	7,000	$0	7,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

2. The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

This amended Form 4, as originally filed on May 14, 2026, is being filed to correct the amount of stock options and RSUs granted to the Reporting Person. This Form 4 amendment updates both equity awards to reflect 7,000 stock options and 2,500 RSUs originally granted to the Reporting Person on May 12, 2026.

	/s/ Ajim Tamboli, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Dennis M. Fenton acquire in this First Tracks Biotherapeutics (TRAX) Form 4/A?

Dennis M. Fenton received two equity awards: stock options for 7,000 shares of common stock at a $17.81 exercise price, and 2,500 restricted stock units, each convertible into one share of common stock for no cash consideration upon settlement.

How do the new TRAX stock options granted to Dennis M. Fenton vest?

The stock options for 7,000 shares vest in 1/12 increments monthly, beginning on June 12, 2026. Vesting continues each month until fully vested, provided Fenton continues to provide service to First Tracks Biotherapeutics on each vesting date.

When do Dennis M. Fenton’s restricted stock units in First Tracks Biotherapeutics (TRAX) vest?

Fenton’s 2,500 restricted stock units vest as to 100% of the total units on the date of First Tracks Biotherapeutics’ 2027 annual meeting of shareholders, so long as he continues to provide service to the company through that vesting date.

What is the exercise price and expiration for Dennis M. Fenton’s TRAX stock options?

The granted stock options carry an exercise price of $17.81 per share and are scheduled to expire on May 11, 2036. These options give Fenton the right to buy First Tracks Biotherapeutics common stock at that fixed price until expiration.

Does Dennis M. Fenton pay cash to receive the TRAX restricted stock units?

No cash payment is required to receive the RSUs. Each restricted stock unit represents a contingent right to receive one share of First Tracks Biotherapeutics common stock upon settlement for no consideration, assuming the vesting conditions are satisfied.